Breakdown | TTM | Dec 2025 | Dec 2023 | Dec 2023 | Dec 2022 | Dec 2021 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 10.66B | 10.87B | 8.05B | 9.34B | 6.99B | 4.31B |
Gross Profit | 2.80B | 2.02B | 3.70B | 2.50B | 3.05B | 1.81B |
EBITDA | 1.68B | 1.60B | 1.61B | 1.98B | 1.30B | 962.41M |
Net Income | 347.99M | 62.22M | 677.01M | 840.77M | 541.25M | 423.96M |
Balance Sheet | ||||||
Total Assets | 0.00 | 17.04B | 12.81B | 16.08B | 11.94B | 9.97B |
Cash, Cash Equivalents and Short-Term Investments | 1.49B | 1.29B | 2.16B | 1.08B | 802.52M | 219.91M |
Total Debt | 0.00 | 4.76B | 1.81B | 3.78B | 1.74B | 541.27M |
Total Liabilities | -10.12B | 7.08B | 3.54B | 6.00B | 3.17B | 1.62B |
Stockholders Equity | 10.12B | 9.92B | 9.28B | 10.00B | 8.76B | 8.35B |
Cash Flow | ||||||
Free Cash Flow | 0.00 | -1.03B | 492.90M | -275.11M | -564.77M | 577.89M |
Operating Cash Flow | 0.00 | -313.01M | 677.73M | 195.96M | 189.17M | 843.49M |
Investing Cash Flow | 0.00 | -433.53M | -610.59M | 380.73M | -602.82M | -569.70M |
Financing Cash Flow | 0.00 | 822.58M | -500.24M | -1.51B | 904.59M | -293.57M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
68 Neutral | ₹32.56B | 43.89 | 17.78% | 0.14% | 15.84% | 79.69% | |
67 Neutral | ₹16.31B | 25.86 | 7.67% | 0.87% | 8.10% | -19.89% | |
60 Neutral | ₹25.66B | 31.85 | 8.79% | 0.35% | 13.78% | 32.21% | |
58 Neutral | ₹26.70B | 1,145.00 | ― | 0.49% | 13.03% | -100.65% | |
55 Neutral | ₹22.40B | 29.99 | 10.81% | 0.16% | 10.29% | 25.18% | |
47 Neutral | ₹24.78B | 215.84 | -1.00% | ― | 11.80% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Shalby Multi-Specialty Hospitals has achieved a significant milestone by performing the world’s first fully autonomous robotic joint replacement surgery. This innovative technology, featuring a saw-based robotic arm with 7-axis movement, enhances surgical precision and reduces recovery time, reinforcing Shalby’s position as a leader in orthopedic innovation. The advancement is expected to benefit millions globally by providing safer and more precise surgeries.